Canadian CBD company Akseera Pharma Corp said on Monday that it is leading the research surrounding CBD and COVID-19 and has collaborated with premier universities to study the potential of CBD in the prevention and prophylaxis of COVID-19.

According to the company, it owns patents for use of CBD for COVID-19 shown in this research as well as holds patents for the appropriate dosages, delivery systems and timing of administration with CBD for COVID prevention and treatment.

In SARS-CoV-2, the cells should activate an innate system that cuts up the viral genome, which causes infected cells to undergo a process called apoptosis – a sort of controlled cell death that gets rid of infected cells early on. When combined with the company's patented dose of CBD with viral proteins, the combination had a much better ability to activate this system and to activate apoptosis.

Under a study, the patients taking the company's prescription high-dose CBD showed a ten fold lower risk of testing positive for COVID-19.

Additionally, the company said its CBD product may supplement vaccines or be of use in population groups that do not have access to the vaccine; especially in countries where vaccinations face logistical challenges.